Gastroenterology
Conference Coverage
Mortality Rates From Early-Onset CRC Have Risen Considerably Over Last 2 Decades
Increased mortality occurred across all patients included in the study (aged 20-54) regardless of tumor stage at diagnosis.
News
Molecular Stool Testing Could Cut Post-Polypectomy Colonoscopies by 15%-41%
A noninvasive strategy could ease the surveillance burden on healthcare resources and be more palatable to patients.
From the Journals
Risk Assessment Tool Can Help Predict Fractures in Cancer
Researchers collected data on bone mineral density and fractures in 9,877 patients with cancer and 45,875 matched control individuals without...
Commentary
The New Cancer Stats Might Look Like a Death Sentence. They Aren’t.
Data show that people under 50 are experiencing higher rates of cancer than any generation before them.
From the Journals
True Benefit of Screening Colonoscopy for CRC Underestimated in NordICC
Registration delays of 1, 2, or 3 years led to an underestimated risk for CRC by 25%, 50%, and 75%, respectively.
From the Journals
MMR/MSI Testing for CRC Climbs, But Variations Persist
To assess trends and factors associated with MMR/MSI testing, researchers evaluated 834,797 patients diagnosed with stage I to IV CRC between 2012...
Commentary
Are Targeted Drugs the Future in Colorectal Cancer?
Preliminary results from three trials suggest some benefits of cetuximab plus irinotecan in patients who’d already had epidermal growth factor...
News from the FDA/CDC
FDA OKs Next-Gen Cologuard Test for CRC Screening
Cologuard Plus tests for three novel methylated DNA markers and fecal hemoglobin.
Conference Coverage
NCCRT Confirmed as Best Approach in Locally Advanced, Resectable ESCC
Researchers compred neoadjuvant concurrent chemoradiotherapy with adjuvant sequential chemoradiotherapy (ASCRT) in locally advanced esophageal...
Latest News
Race Adjustments in Algorithms Boost CRC Risk Prediction
“Removing race from colorectal screening predictors could reduce the number of Black patients recommended for screening.”
News from the FDA/CDC
FDA Panel Votes for Limits on Gastric, Esophageal Cancer Immunotherapy
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted in favor of restricting the use of these immunotherapy agents to patients with PD-L1...